Pharmacologic options for the treatment of overweight and obesity.

Abstract

The field of antiobesity pharmacotherapy is rapidly evolving. FDA-approved medications, such as orlistat, phentermine/topiramate, bupropion/naltrexone, and liraglutide, have significantly improved weight-loss outcomes. Agents such as semaglutide and tirzepatide are setting new standards, achieving weight-loss outcomes comparable to bariatric surgery. These medications not only aid in weight reduction but also offer additional health benefits, including improved cardiometabolic health and reduced cardiovascular risk. Antiobesity medications require long-term use because discontinuation often causes weight regain. Such as other chronic diseases, overweight and obesity require ongoing management. Patient education and support are key to maintaining results and preventing weight recidivism.